A practical, evidence-based guide to the use of adalimumab in Crohn’s disease

Author： Rubin David T.   Panaccione Remo   Chao Jingdong   Robinson Anne M.  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.27, Iss.9, 2011-09, pp. : 1803-1813

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Crohn’s Disease Mimicking Sarcoidosis in Bronchoalveolar Lavage

By  

Respiration, Vol. 66, Iss. 5, 1999-09 ,pp. : 467-469

Karger

Access to resources Recommend Favorite

Multiple Pulmonary Nodules in a Patient with Crohn’s Disease

By  

Respiration, Vol. 70, Iss. 3, 2003-08 ,pp. : 306-309

Karger

Access to resources Recommend Favorite

Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn’s disease

By Sandborn W. J.   Colombel J.-F.   D’Haens G.   Plevy S. E.   Panés J.   Robinson A. M.   Pollack P. F.   Zhou Q.   Castillo M.   Thakkar R. B.  

Current Medical Research and Opinion, Vol. 29, Iss. 5, 2013-05 ,pp. : 483-493

Informa Healthcare

Access to resources Recommend Favorite

Comparison of infliximab with adalimumab in 827 biologic‐naïve patients with Crohn's disease: a population‐based Danish cohort study

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 5, 2018-03 ,pp. : 596-604

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ileum resection is the most predictive factor for osteoporosis in patients with Crohn’s disease

By Hogezand R.   Bänffer D.   Zwinderman A.   McCloskey E.   Griffioen G.   Hamdy N.  

Osteoporosis International, Vol. 17, Iss. 4, 2006-04 ,pp. : 535-542

Springer Publishing Company

Access to resources Recommend Favorite